This proposed score, we called atypical CLL score, markedly improved the sensitivity of CLL diagnosis to 84.2% in atypical CLL group and 79.4% in CD5 negative or CD23 negative CLL group, respectively (Table 2). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.